GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » Beneish M-Score

China Pharma Holding (China Pharma Holding) Beneish M-Score : -1.85 (As of Apr. 26, 2024)


View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.85 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for China Pharma Holding's Beneish M-Score or its related term are showing as below:

CPHI' s Beneish M-Score Range Over the Past 10 Years
Min: -4.34   Med: -3.33   Max: -0.75
Current: -1.85

During the past 13 years, the highest Beneish M-Score of China Pharma Holding was -0.75. The lowest was -4.34. And the median was -3.33.


China Pharma Holding Beneish M-Score Historical Data

The historical data trend for China Pharma Holding's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding Beneish M-Score Chart

China Pharma Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.25 -3.36 -0.75 -3.26 -1.85

China Pharma Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.26 -1.44 1.01 -2.03 -1.85

Competitive Comparison of China Pharma Holding's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Pharma Holding's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Beneish M-Score falls into.



China Pharma Holding Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of China Pharma Holding for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.8136+0.528 * 1.5178+0.404 * 1.7841+0.892 * 0.8651+0.115 * 0.7625
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8759+4.679 * -0.145485-0.327 * 0.7013
=-1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.73 Mil.
Revenue was 2.15 + 1.803 + 1.098 + 1.96 = $7.01 Mil.
Gross Profit was -0.079 + -0.233 + -0.147 + 0.178 = $-0.28 Mil.
Total Current Assets was $6.00 Mil.
Total Assets was $16.47 Mil.
Property, Plant and Equipment(Net PPE) was $6.82 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.75 Mil.
Selling, General, & Admin. Expense(SGA) was $2.25 Mil.
Total Current Liabilities was $6.82 Mil.
Long-Term Debt & Capital Lease Obligation was $1.45 Mil.
Net Income was -1.232 + -0.778 + -0.593 + -0.476 = $-3.08 Mil.
Non Operating Income was -0.008 + 0.018 + -0.004 + 0.01 = $0.02 Mil.
Cash Flow from Operations was -0.022 + 1.007 + -0.216 + -1.468 = $-0.70 Mil.
Total Receivables was $0.46 Mil.
Revenue was 2.921 + 1.966 + 1.613 + 1.604 = $8.10 Mil.
Gross Profit was 0.043 + -0.138 + -0.229 + -0.169 = $-0.49 Mil.
Total Current Assets was $5.97 Mil.
Total Assets was $17.78 Mil.
Property, Plant and Equipment(Net PPE) was $9.61 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.70 Mil.
Selling, General, & Admin. Expense(SGA) was $2.96 Mil.
Total Current Liabilities was $12.74 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.728 / 7.011) / (0.464 / 8.104)
=0.103837 / 0.057256
=1.8136

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-0.493 / 8.104) / (-0.281 / 7.011)
=-0.060834 / -0.04008
=1.5178

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5.997 + 6.819) / 16.469) / (1 - (5.965 + 9.608) / 17.784)
=0.221811 / 0.124325
=1.7841

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7.011 / 8.104
=0.8651

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.7 / (2.7 + 9.608)) / (2.754 / (2.754 + 6.819))
=0.21937 / 0.287684
=0.7625

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.246 / 7.011) / (2.964 / 8.104)
=0.320354 / 0.365745
=0.8759

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.452 + 6.821) / 16.469) / ((0 + 12.739) / 17.784)
=0.502338 / 0.716318
=0.7013

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3.079 - 0.016 - -0.699) / 16.469
=-0.145485

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

China Pharma Holding has a M-score of -1.85 suggests that the company is unlikely to be a manipulator.


China Pharma Holding Beneish M-Score Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


China Pharma Holding (China Pharma Holding) Business Description

Traded in Other Exchanges
N/A
Address
Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Executives
Ke Deng 10 percent owner NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung officer: Chief Financial Officer 72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett director 4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang director NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong director NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui director, 10 percent owner FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li officer: President and CEO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang officer: Secretary NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu officer: CFO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond 10 percent owner 174 FM 1830, ARGYLE TX 76226
David F Brigante 10 percent owner 174FM 1830, ARGYLE TX 76226
Marat Rosenberg 10 percent owner 17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp 10 percent owner 174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc 10 percent owner 174 FM 1830, ARGYLE TX 76226
Timothy P Halter director, 10 percent owner, officer: CEO, President & CFO 174 FM 1830, ARGYLE TX 76226